Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled study of subcutaneous SAR444336 in healthy adults
NL-OMON54131Phase 1Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2021
- Modality
- Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease and inflammatory diseases comparing SAR444336 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events, Clinical laboratory safety evaluations and 2 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
SAR444336
03
Conditions
autoimmune diseaseinflammatory diseases
Beyond the preview
Go deeper on NL-OMON54131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54131.